Envestnet Asset Management Inc. Buys 16,886 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Envestnet Asset Management Inc. raised its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 259,429 shares of the medical instruments supplier's stock after purchasing an additional 16,886 shares during the period. Envestnet Asset Management Inc. owned approximately 1.15% of LeMaitre Vascular worth $23,904,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. FMR LLC lifted its position in shares of LeMaitre Vascular by 330.6% during the 3rd quarter. FMR LLC now owns 10,568 shares of the medical instruments supplier's stock worth $982,000 after buying an additional 8,114 shares during the last quarter. State Street Corp boosted its stake in shares of LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock valued at $76,363,000 after purchasing an additional 28,525 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at approximately $344,000. MML Investors Services LLC increased its position in LeMaitre Vascular by 2.8% during the 3rd quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier's stock worth $660,000 after purchasing an additional 191 shares in the last quarter. Finally, Barclays PLC lifted its stake in LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $95.25.

LeMaitre Vascular Stock Up 1.9 %

Shares of NASDAQ LMAT traded up $1.61 during trading on Friday, reaching $86.28. The company had a trading volume of 184,020 shares, compared to its average volume of 160,817. The stock has a market cap of $1.95 billion, a P/E ratio of 47.15, a PEG ratio of 2.22 and a beta of 0.89. The company's fifty day moving average price is $87.85 and its 200-day moving average price is $93.48. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts' consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.93%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is 41.24%.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.